January 9, 2017
US $38M; Potential Expansion into Other Asia/Pacific Countries, Additional Liquid Biopsy Products
Biodesix, Inc. (Boulder, CO, USA) and Bioyong Technology Company Ltd. (Beijing, China) announced today that they have entered into an international collaboration agreement where Bioyong will develop and commercialize a version of Biodesix’s VeriStrat® proteomic blood test, a precision medicine diagnostic for patients with non-small ... Read more
December 13, 2016
VeriStrat® Test Shown To Have Clinical Utility in Predicting Overall Survival of Afatinib-Treated Patients With Lung Cancer
December 13, 2016, Boulder, Colorado… Two studies demonstrating the clinical utility of the VeriStrat® test in the management of patients with non-small cell lung cancer (NSCLC) were presented last week at the 17th World Conference on Lung Cancer, hosted ... Read more
December 7, 2016
Biodesix won the award for “Innovative Company of the Year” last night at the 2016 IQ Awards and Innovation Summit presented by BizWest Media. The other finalists in the category were Fort Collins-based Madwire and n.io of Broomfield.
“We are really in the business of helping cancer patients to determine the most effective treatment for their ... Read more
November 15, 2016 “The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision to optimize benefit,” said Dr. Jeffrey Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU-Langone Medical Center in New York City.
November 12, 2016
Biodesix Presents Data from Two Studies at 2016 AMP Annual Meeting
Biodesix® is presenting two posters with results of separate genomics studies at the AMP 2016 Annual Meeting. In the first study, analysis of blood test results from non-small cell (NSCLC) lung cancer patients who tested EGFR wild-type, and have Poor prognosis as determined by the ... Read more
November 8, 2016
Blood-Based Assays to Predict Response to Combination Checkpoint Blockade, High dose interleukin 2 (HDIL-2) in Melanoma
November 8, Boulder, Colorado…Three studies involving the development and validation of Biodesix’ blood-based proteomic tests, to aid in patient selection or predicting outcomes in the use of immunotherapies, will be presented this week at SITC’s 31st Annual Meeting.
Oral Poster Presentation:
Date and ... Read more
October 31, 2016 Based on published clinical data, Humana, Medical Mutual of Ohio and Preferred One independently determined and published policy stating that VeriStrat can be considered medically necessary for patients with advanced NSCLC.
October 26, 2016
Independent Data Demonstrates Clinical Utility of Biodesix®’ Blood-Based Tests
Biodesix’ tests facilitate rapid treatment decisions and prognostic conversations
October 26, 2016, Boulder, Colorado – Data from Gundersen Health System, La Crosse, WI, externally verified the clinical significance of GeneStrat® and VeriStrat® blood-based testing for patients with non-small cell lung cancer (NSCLC). Blood-based Genomic and Proteomic Testing for Newly Diagnosed Lung Cancer ... Read more
October 10, 2016
Independent Study Data Supporting Clinical Use of Biodesix® Blood-Based Tests To Be Presented At CHEST Conference
Learning Theater Presentation Focused On Multi-Disciplinary Approach
An independent study in patients with non-small cell lung cancer (NSCLC) investigating how blood-based genomic and proteomic testing can be used to facilitate faster treatment decisions will be presented at the CHEST Annual Meeting in ... Read more
October 5, 2016
Biodesix’ blood-based VeriStrat test helps identify squamous NSCLC patients for EGFR-TKI therapy
BOULDER, Colo., October 5, 2016 – New clinical findings show that the Biodesix® VeriStrat test identifies patients with squamous cell carcinoma of the lung who are more likely to have longer progression-free and overall survival (PFS and OS) with irreversible ErbB family blocker afatinib ... Read more